​AmeriHealth continues to designate Lantus^® (insulin glargine) as one of its preferred long-acting insulin drugs used to manage diabetes.

On July 28, 2021, the U.S. Food and Drug Administration (FDA) approved new NDCs for Semglee^® and its authorized generic insulin glargine-yfgn as interchangeable biosimilars to Lantus. However, when considering all discounts that are passed along to members or their employer groups, Lantus is still the more cost-effective product. 

During the first quarter of 2022, AmeriHealth will continue to monitor the marketplace regarding these products and review its position on these medications as needed. Member disruption and continued access to cost-effective medications will be considered.

Providers will be notified via the Provider News Center if any changes are made to the preferred drug.